Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024)

Summary

Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024) is a study catalogued by cBioPortal DataHub under the cancer-type code mixed. EvidenceHelix groups it with multiple or not classified from the title studies.

Study description

Targeted sequencing of 1,007 cerebrospinal fluid circulating tumor DNA from patients with central nervous system tumors using MSK-IMPACT and their matched normals.

Text as published in the source's study metadata.

Citation & PubMed

Hickman, Richard A et al. Acta neuropathologica communications 2024

Linked PubMed records: PMID 39289779

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

csf_msk_2024

Short name

not given

Source cancer-type code

mixed

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Hickman, Richard A et al. Acta neuropathologica communications 2024

• PubMed record 39289779 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• BRAF Fusions - ARCHER Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 107 clinical cases via ARCHER to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complement…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 105 clinical cases via MSK-IMPACT to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is comple…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)

  Targeted sequencing of 47,532 patient samples with mixed tumor types and their matched normals to identify clonal hematopoiesis mutations using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Clin Cancer Res 2022)

  Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)

  Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Mixed cfDNA (MSK, Nature Medicine 2019)

  Targeted sequencing of 248 samples from 124 patients' cfDNA/WBC and tumor/normal pairs.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Mixed Tumors - MiMSI Cohort (MSK, Nat Commun 2024)

  Targeted sequencing of 5,033 clinical cases and their matched normals via MSK-IMPACT, with pathologist-confirmed orthogonal MMR IHC data.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)

  Targeted sequencing of Selpercatinib treated RET-driven solid cancers.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.